In conclusion, we emphasize that CD90 confers aggressiveness in iCCA and that the interaction with TGF-β1 could be a characteristic on which to stratify patients with iCCA who are suitable for combination therapy, paving the way toward the adoption of new personalized therapeutic strategies. Here, TGFB1 is linked to infantile convulsions and choreoathetosis.